The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo®) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1 Multikine* is uniquely ...
A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses. Their ...
News Medical on MSN
Study offers a practical strategy to enhance effectiveness of immune checkpoint inhibitors
Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.
Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework Observational studies or ...
Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements. Patients with advanced non-small cell lung cancer ...
The FDA approved Scancell's phase 3 trial of iSCIB1+ for advanced melanoma, focusing on progression-free survival as a ...
Outcomes of patients with concurrent chronic lymphocytic leukemia and non-small cell lung carcinoma. Circulating tumor DNA as a prognostic biomarker for long-term survival in de-novo oligometastatic ...
Patients with Glioblastoma (GBM), a highly aggressive malignant brain tumor, have an extremely poor prognosis due to a lack of viable treatment choices. Since being named the “breakthrough of the year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results